Kornimate/medical-research-clean huggingface dataset:
real-world retrospective data analysis of adjuvant therapy for patients with stage ii-iii colon cancer after radical surgery

Conditions: Stage II Colon Cancer; Stage III Colon Cancer; Adjuvant Therapy

Summary: background: 1. . the incidence and mortality of colon cancer are high in china and in the world. 2. . the treatment of many patients in the real world is not standardized, and there are problems such as over-treatment or under-treatment. to explore the adjuvant treatment of colon cancer in the chinese population, this study will retrospectively analyze real-world data on adjuvant therapy for colon cancer in chinese patients after radical surgery. the purpose of research: 1. . current status of adjuvant therapy for stage ii-iii colon cancer in the real world: chemotherapy regimen, chemotherapy time, efficacy, safety, etc. 2. . comparison of efficacy and safety of different adjuvant chemotherapy time (\ =3 months) in high-risk stage ii and iii colon cancer patients in the real world 3. . comparison of efficacy and safety of different adjuvant chemotherapy regimens (xelox vs. folfox) in high-risk stage ii and iii colon cancer patients in the real world


Eligibility criteria:
inclusion criteria: * patients who are sick after january 2010 * age is older than 18 * surgical pathology confirmed tnm stage ii-iii (ajcc 7th edition) colon cancer exclusion criteria: * combine other tumors * pathological information is not clear * researchers believe that other reasons are not suitable for enrollment

Keywords: current status chemotherapy regimen chemotherapy time efficacy safety adjuvant therapy stage ii-iii colon cancer rws(real world study)
vr for patients with chronic pain (wait & work)

Conditions: Chronic Pain

Summary: this cluster-rct evaluates the effect of therapeutic virtual reality (vr) on patients with chronic musculoskeletal pain (cmp) who are on a waiting list to receive pain treatment. the used vr application, reducept, offers pain education and pain management techniques. this home-based, stand-alone, immersive vr intervention was used daily for four weeks in the intervention group. the control group received standard care (no treatment). primary outcome measure for this study was health-related quality of life, secondary outcome measures included various pain-related variables (e.g. pain self-efficacy and acceptance. outcome variables will be measured after four weeks and follow-up after six months.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * suffering from primary or secondary cmp * finished with biomedical diagnostics and treatment * open to biopsychosocial treatment * willing and capable of complying with study procedures. exclusion criteria: * not able to finish the vr intervention due to physical (e.g. visual impairment), mental (e.g. severe sensitivity to stimuli) or practical problems (e.g. insufficient tech-literacy) * unable to finish dutch questionnaires.
intellivent asv in chronic obstructive pulmonary disease patients in the icu

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study will evaluate the effect of a fully closed loop ventilation mode (intellivent asv) on the duration of ventilation compared to conventional modes in copd patients.

copd patients often need invasive mechanical ventilation and due to the difficulties in the weaning of these patients, duration of mechanical ventilation can be relatively longer when compared with other icu patients. automated systems show promising results in shortening the weaning time in some patient groups. the aim of this study is to evaluate the effect of intellivent-asv with quickwean function on the total duration of invasive mechanical ventilation as a primary outcome. secondary outcomes are success rate and duration of weaning, ventilator free days at day 28 and intubation free days at day 28 (including niv) when compared to conventional ventilation with t-piece weaning.

Eligibility criteria:
inclusion criteria: * copd patients intubated and mechanically ventilated for less than 24 hours (including patients who received niv before intubation) * age \> 18 years * written and/or informed consent exclusion criteria: * septic shock * tracheostomy and/or home mechanical ventilation * expected poor short term prognosis * cardiac arrest with a poor neurological prognosis * ards * broncho-pleural fistula

Keywords: respiration, artificial weaning critical care
the effects of two types of t-dcs stimulation on robot-assisted gait training in patients with multiple sclerosis

Conditions: Multiple Sclerosis; Transcranial Direct Current Stimulation

Summary: the primary aim of this study is to determine the transcranial direct current stimulation and transcutaneous spinal direct current stimulation in addition to robot-assisted walking training in individuals with multiple sclerosis; to examine the effects on motor functions against each other and sham application. secondary aim of this study is to show the relation of these effects with tdcs and ts-dcs through fatigue and quality of life evaluations.

these study is planned to be carried out in the cadde medical center clinic. the patients who will participate in the study will be determined according to the inclusion criteria among the patients who applied to the multiple sclerosis outpatient clinic of istanbul medeniyet university göztepe research hospital, department of neurology. as a result of the power analysis, 36 participants were planned to be included in the study. 20 minutes of non-invasive brain stimulation will be applied to the individuals participating in these study before the 20 minutes robot-assisted walking training (ratg), 3 days a week for 4 weeks. participants will be divided into 3 groups according to the type of stimulation applied by simple randomization. these groups are 1) anodal tdcs + sham ts-dcs; 2) sham tdcs + cathodal ts-dcs 3) sham tdcs + sham ts-dcs. the same evaluations will be applied to all participants during the study and the evaluations are planned as before and after the intervention. the data collected as a result of the evaluations will be analyzed with spss version 22.

Eligibility criteria:
inclusion criteria: * patients diagnosed with ms and suffering from walking difficulties due to ms * edss score between 2-6 * being over 18 years old exclusion criteria: * relapsed within the last two months * changed medication within 45 days * hospitalized in the last three months * had other neurological or musculoskeletal problems * had an obstacle to stimulation (skin problems, metal implants, etc.) * do not want to participate in the study individuals
get ready and empowered about treatment

Conditions: HIV

Summary: the purpose of this study is to rigorously assess a program designed to empower patient living with hiv, to improve their health care and health, and to reduce disparities.

our project has four major aims: 1. assess improvement in patient empowerment 2. assess improvement in patients' receipt of evidence-based care 3. assess improvement in patients' health 4. assess reduction in disparities in empowerment

Eligibility criteria:
inclusion criteria: * age18 years or older, * confirmed hiv diagnosis * receipt of care within a participating site. exclusion criteria: * inability to provide informed consent * limited english proficiency (trainings and personal health record are currently only available in english)
computer-assisted navigation for intramedullary nail fixation of intertrochanteric femur fractures

Conditions: Intertrochanteric Femur Fractures

Summary: there are approximately 250,000 hip fractures in the us every year, and intertrochanteric (it) fractures (fractures that occur just below the femoral head) account for nearly half of these fractures. the use of intramedullary (im) nails for fixation of it femur fractures has become a well-accepted and increasingly more common procedure among orthopaedic traumatologists, and is standard of care at our institution. while advancements in intramedullary nail fixation have made it a relatively efficient procedure, the placement of the lag screw into the femoral head still remains a challenging step in the procedure. inaccurate placement can lead to screw cut-out, one of the most commonly reported complications with im nail fixation. previous work has shown that the lag screw position is an important factor in reducing screw cut-out. this step of the procedure can be time demanding and often requires several intraoperative radiographs for accurate placement. recently developed computer-assisted navigation systems provide surgeons with the ability to track screw placement in real-time. this could allow for improved screw placement and potentially reduce radiation exposure to the patient and surgeon. to date, the potential advantages of computer-assisted navigation have not been examined. the primary objective of this study is to examine whether the use of stryker's adapt computer-assisted navigation for gamma nail fixation can result in improved lag screw placement. the secondary objective is to examine whether the use of the adapt for gamma nail fixation can reduce intraoperative radiation exposure.our hypothesis is that there is a difference in the lag screw placement (i.e. tip to apex distance measurement) between procedures using the adapt system versus the conventional technique for gamma nail fixation. additionally, we hypothesize that there is a difference in radiation exposure (i.e. fluoroscopy time) between procedures using the adapt system versus the conventional technique for gamma nail fixation.


Eligibility criteria:
inclusion criteria: * patients undergoing hip fracture fixation with a gamma nail by one of four orthopaedic trauma surgeons at william beaumont hospital royal oak * diagnosis of an intertrochanteric femur fracture (ao classification 31-a1,a2) * low energy mechanism of injury (i.e. fall, twist) exclusion criteria: * minors (less than 18 years) * pregnant * have a high energy mechanism of injury (e.g. motor vehicle accident, fall from height) * have an open fracture (i.e. the skin is broken at the fracture site), or * present with multiple injuries to the ipsilateral lower extremity

Keywords: computer-assisted navigation adapt intramedullary nail intertrochanteric femur fracture
pain and sensation after regional anesthesia - pilot study

Conditions: Anesthesia, Conduction; Osteoarthritis, Hip

Summary: this study aims to determine spinal resolution and pain levels after the placement of a lumbar plexus block (lpb) and spinal for total hip replacement procedure. this is a pilot study that looks to collect information in order to design a larger, more significant study comparing quadratus lumborum blocks (qlb) and lumbar plexus blocks.

the quadratus lumborum block (qlb) is a newer regional analgesic technique that may be as effective as lumbar plexus blocks (lpb) at providing pain control following direct anterior approach (daa) hip arthroplasty. the purpose of this study is to collect pilot data to help the design of a future randomized study, comparing a qlb to a lpb for daa procedures. the investigators will assess for spinal resolution below the level of l5/s1 by assessing the presence of pin prick sensation at these levels. this will help determine if pain scores collected at 6hrs reflect analgesia provided by the preoperative lpb alone or if the data is confounded by the presence of spinal anesthesia. this data will help us determine if 6hrs is a feasible primary endpoint to assess pain scores. additionally, assuming that spinal regression is complete by 6hrs, the vas pain scores obtained will then be used to perform a power analysis to determine the necessary study size when comparing qlb to lpb for daa hip arthroplasty.

Eligibility criteria:
inclusion criteria: * patients that have elective total hip arthroplasty with daa at davie medical center. exclusion criteria: * patients will be excluded if they do not receive a lumbar plexus block and spinal anesthesia. * and/or if they have peripheral neuropathy affecting their feet.

Keywords: lumbar plexus block total hip arthroplasty arthroplasty, direct anterior approach pain
assessment of functional digestive and genitourinary outcomes in patients with rectal cancer.

Conditions: Rectal Cancer; Surgery

Summary: total mesorectal excision and neoadjuvant radio-chemotherapy have revolutionized the management of rectal cancer allowing an increase in survival (between 55 and 68% at 5 years) and allowing a decrease of local recurrence (under 10%) and allowing to push the limits of sphinctyer saving procedures. parallel to the oncological findings, evaluating quality of life and functionnals sequelae has become a priority as highlighted by the second axis of "plan cancer 2014-2019". the prevalence of digestive functional sequelae decrease during the first two years after surgery. however, these results are difficult to analyse due to the heterogeneity of used scores in medical litterature. the low anterior resection syndrom associate poly-exoneration, gas and / or stool incontinence, urgency and stool splitting. the score of low anterior resection " lars score " validated in danemark in 2012 allow us to understand the complexity of these sequelae and to measure their impact on the quality of life of patients, that's why he is currently recommended. in the long term, almost two out of three patients suffer from this syndrom, with half of the patients in a severe form. however, its prevalence and severity are often underestimated by practitioners. it leads to inappropriate therapeutic measures. the aim of this study is to evaluate the impact of digestive and genito-urinary sequelae on quality of life from validated scores in patients operated curatively of rectal cancer using a population study. this study should include 676 patients with rectal cancer treated in calvados and alive at 2 years of their proctectomy without local or general recurrence.


Eligibility criteria:
inclusion criteria: * patients operated for a rectal adénocarcinoma with a curative aim with or without neo-adjuvating treatment in calvados between january 1st, 2007 (date of recommendations for clinical practise) and december 31 th, 2014. * patients having their main address in the calvados (at the time of diagnosis) and recorded in the register of digestive tumors of the calvados. * patients alive on first of january 2018 without local recurrence nor global recurrence * patients able to understant a validated questionnaire. exclusion criteria: * dead patients * patients with cancer recurrence * patient with severe cognitive disorders (confusions) preventing the good understanding of questionnaires.

Keywords: rectal cancer proctectomy digestive sequelae quality of life urinary and sexual sequelae
non-interventional study to assess adherence to treatment for patients with rms (main-ms)

Conditions: Relapsing Multiple Sclerosis (RMS)

Summary: this is an open label, non randomized, uncontrolled, multicenter, single arm observational study. in this study, the enrolled subjects will be treated with rebif human serum albumin (hsa)-free formulation (with or without rebismart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.


Eligibility criteria:
inclusion criteria: * male and female subjects aged more than or equal to (\>=) 18 years and less than or equal to (\<=) 60 years at the time of rebif introduction * subjects diagnosed with rms according to the revised mcdonald criteria (2010) * treatment naïve or subjects on other dmds who will switch to rebif. * subjects will receive 1st rebif 44 mcg dose after signing informed consent * subjects willing and able to provide signed informed consent. exclusion criteria: * have any contraindications to treatment with ifn beta-1a sc according to european summary of product characteristics (eu spc)/prescribed information * subjects participating in other clinical studies/trials * any female subject of childbearing potential who is not on contraceptives * subjects refusal to participate in the study.

Keywords: relapsing multiple sclerosis interferon beta-1a rebif® morisky green levine medication adherence scale
calcium for prevention of ovarian hyperstimulation syndrome

Conditions: Ovarian Hyperstimulation Syndrome

Summary: there are many protocols for prevention of ovarian hyperstimulation syndrome, intravenous calcium is a novel protocol. but still there is lack of evidence of it is real effect in prevention of ohss \& the mechanism of its action is still questionable . in the study the investigators try to search for the evidence for its effect \& the real mechanism for its action.

the study population will be divided into 2groups each containing 100 infertile couples candidate for icsi. group (a)active group: administration of 10% intravenous calcium gluconate 10 ml in 200 ml of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup. intravenous infusion was performed within 30 minutes. group (b): placebo group: administration of 200 ml of 0.9% saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup. intravenous infusion was performed within 30 minutes

Eligibility criteria:
inclusion criteria: * infertile women aged 20 to 38 years. * bmi ranged from 18 to 40. * serum fsh within normal limits( 1-12iu /l) * presented with ovarian response suggestive of being at risk of developing ohss because of the presence of at least 15 follicles of 10 mm or greater on the day of hcg administration. exclusion criteria: * endocrinopathies. * a systemic disease. * using any medication (e.g., insulin-sensitizing drugs and gnrh antagonists. * patients need coasting for high risk of ohss. * patients need cycle cancellation. * severe male infertility requiring testicular sperm extraction.

Keywords: ohss icsi calcium injection
a phase 3 trial of alimta (ly231514, pemetrexed) plus gemzar versus gemzar in patients with unresectable or metastatic cancer of the pancreas.

Conditions: Pancreatic Neoplasms; Metastases, Neoplasm

Summary: definition: this study will compare the drug gemzar to a combination of gemzar plus alimta for the treatment of cancer of the pancreas. patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery or that has spread to a new site in their body.


Eligibility criteria:
inclusion criteria: * pancreas cancer that cannot be removed by surgery or that has spread to a new site in your body. * you must have one tumor that can be physically measured or scanned by the doctor. * you have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-fu. * you cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis. exclusion criteria: * treatment with any medication or device that has not been approved by regulatory agencies, like the fda, at the time you enter the study. * documentation that the cancer has spread to your brain. * pregnant or breastfeeding. * a second primary cancer. * unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.

Keywords: pancreas cancer unresectable or metastatic cancer of the pancreas alimta
self drainage in pediatric cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: in the current study, we designed a cross-over, open label, randomized controlled clinical trial that aim to investigate the superiority of physical exercise coupled with self drainage to a chest physiotherapy in stable cystic fibrosis children. we hypothesized that cf children undergoing physical exercise coupled to self drainage will increase the amount of expectorate secretions compared to conventional cp course, while being more satisfied and without worsening their pulmonary function status.


Eligibility criteria:
inclusion criteria: * cystic fibrosis diagnosis confirmed by 2 positive sudoriparous diagnostic tests * age : 7 to 17 years * capacity to expectorate * clinically stable * ability to pedal on a bike and to respect orders for physical session exclusion criteria: * haemoptysis \> 50ml * permanent non-invasive ventilation * respiration or digestive evolutive clinical abnormality * exacerbation

Keywords: cystic fibrosis lung function physical exercise
potential of circulating tumor dna to assess the tumor response to neoadjuvant chemotherapy in breast cancer patients

Conditions: Breast Cancer; Neoadjuvant Chemotherapy; Circulating Tumor DNA

Summary: breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(nac) before the curative surgery.circulating tumor dna(ctdna) is the circulating free dna in the blood that originates from cancers,and it can be detected by modern technologies in plasma.in this prospective study,investigators aim to observe the correlation between tumor response to neoadjuvant chemotherapy and ctdna.

women with node-positive breast cancer are at high risk for recurrence. neoadjuvant chemotherapy is traditionally for locally advanced disease, converting an inoperable tumor to a resectable one.in the present study, investigators will focus on breast cancer patients whose primary tumors are large or have lymph node metastases and need to receive neoadjuvant chemotherapy from 2018 to 2019. circulating tumor dna(ctdna) will be obtained from peripheral blood,and the blood samples will be taken before the neoadjuvant chemotherapy、during the chemotherapy、 before the surgery and post surgery visit (within 24 hours after surgery) .investigators will collect tissue samples both from the breast lump biopsy and the curative surgery. investigators aim to investigate whether circulating tumor dna is a sensitive marker to monitor the efficacy of neoadjuvant chemotherapy in breast cancer.

Eligibility criteria:
inclusion criteria: * female patients undergoing neoadjuvant chemotherapy * age: 18-70 yrs * any menopausal status * any hormone receptor status * invasive breast cancer proven histologically at diagnosis (before neoadjuvant chemotherapy): * locally advanced tumor * patients who received 6 to 8 cycles of neoadjuvant chemotherapy. exclusion criteria: * failed to retain blood sample before nac * lost more than 2 blood samples during nac